15:40:13 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-29 Kvartalsrapport 2024-Q2
2024-04-26 Årsstämma 2024
2024-04-09 Bokslutskommuniké 2023
2023-09-29 Kvartalsrapport 2023-Q2
2023-04-24 Ordinarie utdelning ABS 0.00 NOK
2023-04-21 Årsstämma 2023
2023-03-29 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning ABS 0.00 NOK
2022-05-05 Årsstämma 2022
2022-04-07 Bokslutskommuniké 2021
2021-11-10 Extra Bolagsstämma 2021
2021-08-26 Kvartalsrapport 2021-Q2

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriBioteknik
Arctic Bioscience är ett bioteknikföretag som utvecklar och kommersialiserar läkemedelsprodukter och kosttillskott baserade på bioaktiva marina råvaror. Företaget utvecklar HRO350, en ny läkemedelskandidat för behandling av patienter med mild till måttlig psoriasis. Kosttillskott säljs globalt både som bulkingredienser och som färdiga produkter under varumärket ROMEGA, till både företag och privatkunder.
2022-04-11 21:57:11
Christer L. Valderhaug, CEO of Arctic Bioscience, has today bought 10,000 shares
in Arctic Bioscience at an average price of NOK 15.4925 per share. Following the
transaction, Christer L. Valderhaug holds 10,000 shares and 250,000 share
options in Arctic Bioscience.

Please refer to the attached notification of trading for further details.

This information is subject to the disclosure requirements pursuant to
Regulation EU 596/2014 (MAR) article 19 number 3 and the Norwegian Securities
Trading Act § 5-12.

For more information, please contact

Danielle Glenn

CFO Arctic Bioscience

Phone: +47 909 98 201

E-mail: danielle@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
nutraceutical and pharmaceutical products based on unique bioactive marine
compounds from herring roe.

The company is developing HRO350 - a novel investigational drug candidate based
on herring roe. HRO350 is being developed for treatment of patients with mild-to
-moderate psoriasis. This is a large patient group in need of new effective
medicines with beneficial safety profile.

Herring roe contains lipids that are essential in maintaining cell membranes and
omega -3 fatty acids that contribute to the normal functioning of brain, heart,
and vision. Nutraceuticals from Arctic Bioscience are sold globally as bulk
ingredients as well as finished goods under the ROMEGA® brand. The strategy is
to switch sales from bulk to finished goods and focus markets are USA and China.

Arctic Bioscience is led by a team of highly competent people with experience in
developing marine oils and experience from global pharmaceutical companies.